Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 30Glioblastoma 28Breast Neoplasms 19Lung Neoplasms 17Carcinoma, Non-Small-Cell Lung 17Oropharyngeal Neoplasms 14Squamous Cell Carcinoma of Head and Neck 11Sarcoma 10Glioma 10Esophageal Neoplasms 10Brain Neoplasms 10Urinary Bladder Neoplasms 9Astrocytoma 9Gliosarcoma 8Triple Negative Breast Neoplasms 7Neoplasm Metastasis 7Mouth Neoplasms 7Uterine Cervical Neoplasms 6Rectal Neoplasms 6Melanoma 6Head and Neck Neoplasms 6Carcinoma, Hepatocellular 6Carcinoma 6Adenocarcinoma Of Esophagus 6Stomach Neoplasms 5Pancreatic Neoplasms 5Neoplasms 5Laryngeal Neoplasms 5Esophageal Squamous Cell Carcinoma 5Carcinoma, Squamous Cell 5

Interventions

atezolizumab 4Specimen Handling 2Magnetic Resonance Spectroscopy 2Etoposide 2Carboplatin 2talazoparib 1lipoarabinomannan 1Radiotherapy 1Radiation 1Lamivudine 1LB100 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Extensive Stage Lung Small Cell Carcinoma × Radiation × 1 year × Clear all
NCT04402788 2026-06-02

Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

National Cancer Institute (NCI)

Phase 2/3 Recruiting
138 enrolled

Extensive Stage Lung Small Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡